Drug that slows down the progression of Alzheimer’s disease approved in the US 07/07/2024, 21:37

Donanemab, the second drug against Alzheimer’s disease, has been approved in the US. According to reports, it aims to slow the progression of dementia Daily mail.

Donanemab targets the removal of beta-amyloid protein aggregates. These structures are believed to be responsible for the loss of nerve cells and symptoms of Alzheimer’s disease. Clinical studies have shown that the drug can slow brain decline by up to 35%. After a year and a half, those taking the drug had 84% less amyloid buildup than those in the placebo group.

The drug is administered intravenously once a month. One vial will cost $695.

Despite major progress in treating Alzheimer’s disease, experts have raised concerns about Donanemab due to the risk of brain hemorrhage. Several deaths occurred during the study. 25% developed brain edema.

Before this, the drug Lekanemab, which is currently used to treat Alzheimer’s patients, was approved in the USA.

Earlier scientists in the name drugs that can shrink the brain.

What are you thinking?

Source: Gazeta


More from author

Zakharova answered the question of whether Moscow will lift sanctions against Vance 18:04

The issue of lifting sanctions against US Senator JD Vance is not on the agenda of the Russian Foreign Ministry. The official representative of...

Russians will be able to object to being included in the scammers’ database 16:51

Citizens of the Russian Federation will be able to object to the inclusion of their personal information in the suspicious transactions database, reports Bank...

In Crimea, some cities and towns will be temporarily disconnected from the network 17:53

In addition to Yalta, Feodosia and Kerch, temporary power outages will be imposed in some other settlements in Crimea. The Telegram channel reports »Krymenergo" “Due...